Biopharma startup MindMed, along with collaborators at Switzerland’s University Hospital Basel and the University Hospital of Psychiatry, has announced top line data from a phase 2 trial testing LSD as a treatment for major depressive disorder. The results are encouraging.
The trial found that LSD had “significant, rapid, durable, and beneficial” effects on major depressive disorder (MDD), reducing depression symptoms compared to a control group.
“We are extremely encouraged by the results we presented today, which demonstrate the strong, rapid and enduring improvements of this compound in patients suffering from MDD,” co-primary investigator Matthias Liechti of University Hospital Basel (UHB) said in a statement.
link
LSD effective as major depression therapy in phase 2 trial
American Buddhist Net 